Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis

Eman Hasan1, Samuel Olusi2, Adel Al-Awadhi3, Khalid Mokaddem1, Prem Sharma4, Sunila George21Rheumatic Disease Unit, Al-Amiri Hospital, Ministry of Health, Kuwait; 2Department of Pathology, Faculty of Medicine, Kuwait University, Kuwait; 3Department of Medicine, Faculty of Medicine, Kuwait University...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hasan E, Olusi S, Al-Awadhi A, Mokaddem K, Sharma P, George S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/7dd9ded1fade44c59ee08f16571fc738
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7dd9ded1fade44c59ee08f16571fc738
record_format	dspace
spelling	oai:doaj.org-article:7dd9ded1fade44c59ee08f16571fc7382021-12-02T07:56:06ZEffects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis1177-54751177-5491https://doaj.org/article/7dd9ded1fade44c59ee08f16571fc7382012-02-01T00:00:00Zhttp://www.dovepress.com/effects-of-rituximab-treatment-on-the-serum-concentrations-of-vitamin--a9181https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Eman Hasan1, Samuel Olusi2, Adel Al-Awadhi3, Khalid Mokaddem1, Prem Sharma4, Sunila George21Rheumatic Disease Unit, Al-Amiri Hospital, Ministry of Health, Kuwait; 2Department of Pathology, Faculty of Medicine, Kuwait University, Kuwait; 3Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait; 4Computer Unit, Health Sciences Center, Kuwait University, KuwaitBackground: Rituximab, a monoclonal antibody that selectively targets CD20-positive B-lymphocytes, is used for the treatment of patients with rheumatoid arthritis (RA) with an inadequate response or tolerance to tumor necrosis factor inhibitors. The objective of this study was to investigate the effects of rituximab treatment on the serum concentrations of vitamin D, interleukin (IL) 2, IL-6, IL-7, and IL-10 in patients with rheumatoid arthritis (RA).Methods: Forty-five patients, aged 25&ndash;78 years, were enrolled into a cohort prospective study. All patients were treated with intravenous rituximab. Disease activity score-28 (DAS-28) and serum concentrations of rheumatoid factor (RF), C-reactive protein (CRP), anticyclic citrullinated peptide (anti-CCP), erythrocyte sedimentation rate (ESR), health assessment questionnaire (HAQ), vitamin D, ILs 2, 6, 7, and 10 were estimated in the patients before and after treatment with rituximab.Results: DAS-28, HAQ score, and serum concentrations of CRP, RF, anti-CCP, IL-2, IL-6, IL-7, IL-10, and ESR significantly decreased after treatment. All 45 patients had vitamin D deficiency before treatment and this did not significantly change after treatment. However no significant association was found among serum vitamin D concentration and any of the ILs.Conclusion: We concluded from this study that although rituximab treatment of patients with RA significantly reduced their disease activity and serum concentrations of IL-2, IL-6, IL-7, and IL-10, it did not significantly alter their vitamin D status. Furthermore, no significant association was found among serum vitamin D concentration and any of the ILs.Keywords: vitamin D, rituximab treatment, rheumatoid arthritis, interleukinsHasan EOlusi SAl-Awadhi AMokaddem KSharma PGeorge SDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 31-35 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Hasan E Olusi S Al-Awadhi A Mokaddem K Sharma P George S Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis
description	Eman Hasan1, Samuel Olusi2, Adel Al-Awadhi3, Khalid Mokaddem1, Prem Sharma4, Sunila George21Rheumatic Disease Unit, Al-Amiri Hospital, Ministry of Health, Kuwait; 2Department of Pathology, Faculty of Medicine, Kuwait University, Kuwait; 3Department of Medicine, Faculty of Medicine, Kuwait University, Kuwait; 4Computer Unit, Health Sciences Center, Kuwait University, KuwaitBackground: Rituximab, a monoclonal antibody that selectively targets CD20-positive B-lymphocytes, is used for the treatment of patients with rheumatoid arthritis (RA) with an inadequate response or tolerance to tumor necrosis factor inhibitors. The objective of this study was to investigate the effects of rituximab treatment on the serum concentrations of vitamin D, interleukin (IL) 2, IL-6, IL-7, and IL-10 in patients with rheumatoid arthritis (RA).Methods: Forty-five patients, aged 25&ndash;78 years, were enrolled into a cohort prospective study. All patients were treated with intravenous rituximab. Disease activity score-28 (DAS-28) and serum concentrations of rheumatoid factor (RF), C-reactive protein (CRP), anticyclic citrullinated peptide (anti-CCP), erythrocyte sedimentation rate (ESR), health assessment questionnaire (HAQ), vitamin D, ILs 2, 6, 7, and 10 were estimated in the patients before and after treatment with rituximab.Results: DAS-28, HAQ score, and serum concentrations of CRP, RF, anti-CCP, IL-2, IL-6, IL-7, IL-10, and ESR significantly decreased after treatment. All 45 patients had vitamin D deficiency before treatment and this did not significantly change after treatment. However no significant association was found among serum vitamin D concentration and any of the ILs.Conclusion: We concluded from this study that although rituximab treatment of patients with RA significantly reduced their disease activity and serum concentrations of IL-2, IL-6, IL-7, and IL-10, it did not significantly alter their vitamin D status. Furthermore, no significant association was found among serum vitamin D concentration and any of the ILs.Keywords: vitamin D, rituximab treatment, rheumatoid arthritis, interleukins
format	article
author	Hasan E Olusi S Al-Awadhi A Mokaddem K Sharma P George S
author_facet	Hasan E Olusi S Al-Awadhi A Mokaddem K Sharma P George S
author_sort	Hasan E
title	Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis
title_short	Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis
title_full	Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis
title_fullStr	Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis
title_full_unstemmed	Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis
title_sort	effects of rituximab treatment on the serum concentrations of vitamin d and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/7dd9ded1fade44c59ee08f16571fc738
work_keys_str_mv	AT hasane effectsofrituximabtreatmentontheserumconcentrationsofvitamindandinterleukins267and10inpatientswithrheumatoidarthritis AT olusis effectsofrituximabtreatmentontheserumconcentrationsofvitamindandinterleukins267and10inpatientswithrheumatoidarthritis AT alawadhia effectsofrituximabtreatmentontheserumconcentrationsofvitamindandinterleukins267and10inpatientswithrheumatoidarthritis AT mokaddemk effectsofrituximabtreatmentontheserumconcentrationsofvitamindandinterleukins267and10inpatientswithrheumatoidarthritis AT sharmap effectsofrituximabtreatmentontheserumconcentrationsofvitamindandinterleukins267and10inpatientswithrheumatoidarthritis AT georges effectsofrituximabtreatmentontheserumconcentrationsofvitamindandinterleukins267and10inpatientswithrheumatoidarthritis
_version_	1718399109689245696

Effects of rituximab treatment on the serum concentrations of vitamin D and interleukins 2, 6, 7, and 10 in patients with rheumatoid arthritis

Ejemplares similares